Subjects:
Free Research Articles
Topics:
transplantation, transplantation conditioning, umbilical cord blood

On page 5630 in the 28 May 2009 issue, there are errors in Table 1. Under the row heading “No. of donors, no. (%),” the row for 1 donor reads “033 (100)” under the “KIR-L mismatched, n = 33” column and “069 (100)” in the “KIR-L matched, n = 69” column. Both entries should read “0.” Also, the row for 2 donors is blank in the same columns. The entries should read “33 (100)” in the “KIR-L mismatched, n = 33 column” and “69 (100)” in the “KIR-L matched, n = 69” column. The corrected table is shown below.

Table 1

Patients, conditioning regimen, and graft characteristics

FactorMA conditioning
RI conditioning
MA vs RI, P
KIR-L mismatched, n = 41KIR-L matched, n = 114PKIR-L mismatched, n = 33KIR-L matched, n = 69P
Median age at transplantation, y (range) 15 (0.6-53) 15.9 (1.0-59) .84 48 (22-69) 52 (6-68) .10 < .01 
Median weight, kg (range) 75.8 (57.2-130.3) 69.8 (33.4-148.6) .30 86.9 (55.9-125.7) 78.5 (22.1-121.8) .31 < .01 
Male, no. (%) 27 (66) 66 (58) .37 22 (67) 45 (65) .89 .36 
Recipient CMV positive, no. (%)
Diagnosis, no. (%) 		14 (34) 73 (64) < .01 14 (42) 44 (64) .04 .91 
 AML 18 (44) 42 (37)  8 (24) 20 (29)   
 ALL 13 (32) 42 (37)  1 (3) 8 (11)   
 CML 3 (7) 11 (9) .86 2 (6) 3 (4) .47 < .01 
 MDS 2 (5) 3 (3)  2 (6) 8 (12)   
 NHL/Hodgkin 4 (10) 8 (7)  17 (52) 24 (35)   
 Other 1 (2) 8 (7)  3 (9) 6 (9)   
Year of transplantation, no. (%) 
 1998-2000 9 (22) 23 (20) .12 0 0 .89 < .01 
 2001-2006 54 (78) 91 (80)  33 (100) 69 (100)   
High-risk disease,* no. (%) 13 (32) 32 (28) .66 21 (64) 30 (43) .06 < .01 
ATG with conditioning, no. (%) 17 (41) 43 (38) .67 8 (24) 22 (32) .43 .13 
GVHD prophylaxis, no. (%) 
 CSA/MPD 16 (39) 44 (39) .99 0 0 na < .01 
 CSA/MMF±MPD 25 (61) 70 (61)  36 (100) 69 (100)   
HLA matching,† no. (%) 
 4/6 25 (61) 59 (52)  28 (85) 45 (65)   
 5/6 14 (34) 42 (37) .42 5 (15) 18 (26) .08 .68 
 6/6 2 (5) 13 (11)  0 6 (9)   
No. of donors, no. (%)   .28   na na 
 1 27 (66) 64 (56)  0 0   
 2 14 (34) 50 (44)  33 (100) 69 (100)   
Conditioning, no. (%) 
 Bu containing 1 (2) 8 (7)  1 (3) 1 (1) .54 < .01 
 Cy/Flu/TBI 24 (59) 70 (61) .75 32 (97) 68 (99)   
 Cy/TBI 16 (39) 36 (32)      
Median infused TNC, ×107 (range) 3.4 (1.0-10.3) 3.8 (1.2-10.8) .51 3.3 (2.0-6.8) 3.6 (1.5-5.9) .26 .72 
Median infused CD34+, ×105 (range) 4.6 (0.9-21.6) 4.0 (0.6-34.8) .49 4.0 (1.1-16.6) 4.6 (1.1-13.7) .84 .40 
Median infused CD3+, ×107 (range) 1.2 (0.1-2.6) 1.3 (0.2-3.2) .32 1.1 (0.1-2.7) 1.4 (0.2-3.1) .07 .62 
Median follow-up among survivors, y (range) 2.2 (1.0-6.8) 2.1 (0.9-7.8) .99 2.0 (1.0-3.5) 1.8 (0.9-5.3) .94 .02 
FactorMA conditioning
RI conditioning
MA vs RI, P
KIR-L mismatched, n = 41KIR-L matched, n = 114PKIR-L mismatched, n = 33KIR-L matched, n = 69P
Median age at transplantation, y (range) 15 (0.6-53) 15.9 (1.0-59) .84 48 (22-69) 52 (6-68) .10 < .01 
Median weight, kg (range) 75.8 (57.2-130.3) 69.8 (33.4-148.6) .30 86.9 (55.9-125.7) 78.5 (22.1-121.8) .31 < .01 
Male, no. (%) 27 (66) 66 (58) .37 22 (67) 45 (65) .89 .36 
Recipient CMV positive, no. (%)
Diagnosis, no. (%) 		14 (34) 73 (64) < .01 14 (42) 44 (64) .04 .91 
 AML 18 (44) 42 (37)  8 (24) 20 (29)   
 ALL 13 (32) 42 (37)  1 (3) 8 (11)   
 CML 3 (7) 11 (9) .86 2 (6) 3 (4) .47 < .01 
 MDS 2 (5) 3 (3)  2 (6) 8 (12)   
 NHL/Hodgkin 4 (10) 8 (7)  17 (52) 24 (35)   
 Other 1 (2) 8 (7)  3 (9) 6 (9)   
Year of transplantation, no. (%) 
 1998-2000 9 (22) 23 (20) .12 0 0 .89 < .01 
 2001-2006 54 (78) 91 (80)  33 (100) 69 (100)   
High-risk disease,* no. (%) 13 (32) 32 (28) .66 21 (64) 30 (43) .06 < .01 
ATG with conditioning, no. (%) 17 (41) 43 (38) .67 8 (24) 22 (32) .43 .13 
GVHD prophylaxis, no. (%) 
 CSA/MPD 16 (39) 44 (39) .99 0 0 na < .01 
 CSA/MMF±MPD 25 (61) 70 (61)  36 (100) 69 (100)   
HLA matching,† no. (%) 
 4/6 25 (61) 59 (52)  28 (85) 45 (65)   
 5/6 14 (34) 42 (37) .42 5 (15) 18 (26) .08 .68 
 6/6 2 (5) 13 (11)  0 6 (9)   
No. of donors, no. (%)   .28   na na 
 1 27 (66) 64 (56)  0 0   
 2 14 (34) 50 (44)  33 (100) 69 (100)   
Conditioning, no. (%) 
 Bu containing 1 (2) 8 (7)  1 (3) 1 (1) .54 < .01 
 Cy/Flu/TBI 24 (59) 70 (61) .75 32 (97) 68 (99)   
 Cy/TBI 16 (39) 36 (32)      
Median infused TNC, ×107 (range) 3.4 (1.0-10.3) 3.8 (1.2-10.8) .51 3.3 (2.0-6.8) 3.6 (1.5-5.9) .26 .72 
Median infused CD34+, ×105 (range) 4.6 (0.9-21.6) 4.0 (0.6-34.8) .49 4.0 (1.1-16.6) 4.6 (1.1-13.7) .84 .40 
Median infused CD3+, ×107 (range) 1.2 (0.1-2.6) 1.3 (0.2-3.2) .32 1.1 (0.1-2.7) 1.4 (0.2-3.1) .07 .62 
Median follow-up among survivors, y (range) 2.2 (1.0-6.8) 2.1 (0.9-7.8) .99 2.0 (1.0-3.5) 1.8 (0.9-5.3) .94 .02 

P values less than .05 are shown in bold for easy identification.

ALL indicates acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; and NHL, non-Hodgkin lymphoma.

*

Disease was defined as standard risk if patients underwent transplantation with AML and ALL in first or second complete remission, CML in first chronic phase, and chemotherapy-sensitive lymphoma in partial or complete remission. Other patients were considered to have high-risk disease.

†

For recipients of 2 UCB units the HLA matching reflects the worst matched of the 2 units.

View Large
© 2015 by The American Society of Hematology
2015
Sign in via your Institution